Design of Novel Vaccines Based on Virus-Like Particles

Overview

Journal Subcell Biochem

Publisher Springer

Specialty Biochemistry

Date 2024 Dec 31

PMID 39738963

Authors

Juan Barcena

Maria Zamora-Ceballos

Esther Blanco

Affiliations

Soon will be listed here.

Abstract

Virus-like particles (VLPs) are formed by viral proteins that, when overexpressed, spontaneously self-assemble into particles that structurally are similar to infectious virus or subviral particles (e.g. the viral capsid). VLPs are appealing as vaccine candidates because their inherent properties (i.e. virus-sized, multimeric antigens, highly organised and repetitive structure, not infectious) are suitable for the induction of safe and efficient humoral and cellular immune responses. VLP-based vaccines have already been licensed for human and veterinary use, and many more vaccine candidates are currently in late stages of evaluation. Moreover, the development of VLPs as platforms for foreign antigen display has further broadened their potential applicability both as prophylactic and therapeutic vaccines. This chapter provides an overview on the design and use of VLPs for the development of new-generation vaccines.

References

Pollard A, Bijker E . A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2020; 21(2):83-100. PMC: 7754704. DOI: 10.1038/s41577-020-00479-7. View

Rodrigues C, Plotkin S . Impact of Vaccines; Health, Economic and Social Perspectives. Front Microbiol. 2020; 11:1526. PMC: 7371956. DOI: 10.3389/fmicb.2020.01526. View

Murdin A, Barreto L, Plotkin S . Inactivated poliovirus vaccine: past and present experience. Vaccine. 1996; 14(8):735-46. DOI: 10.1016/0264-410x(95)00211-i. View

Cottam E, Wadsworth J, Shaw A, Rowlands R, Goatley L, Maan S . Transmission pathways of foot-and-mouth disease virus in the United Kingdom in 2007. PLoS Pathog. 2008; 4(4):e1000050. PMC: 2277462. DOI: 10.1371/journal.ppat.1000050. View

Koff W, Rappuoli R, Plotkin S . Historical Advances in Structural and Molecular Biology and How They Impacted Vaccine Development. J Mol Biol. 2023; 435(13):168113. DOI: 10.1016/j.jmb.2023.168113. View

Mateu M . Assembly, Engineering and Applications of Virus-Based Protein Nanoparticles. Adv Exp Med Biol. 2016; 940:83-120. DOI: 10.1007/978-3-319-39196-0_5. View

Chung Y, Cai H, Steinmetz N . Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications. Adv Drug Deliv Rev. 2020; 156:214-235. PMC: 7320870. DOI: 10.1016/j.addr.2020.06.024. View

Wen A, Steinmetz N . Design of virus-based nanomaterials for medicine, biotechnology, and energy. Chem Soc Rev. 2016; 45(15):4074-126. PMC: 5068136. DOI: 10.1039/c5cs00287g. View

Crisci E, Barcena J, Montoya M . Virus-like particle-based vaccines for animal viral infections. Inmunologia. 2020; 32(3):102-116. PMC: 7115488. DOI: 10.1016/j.inmuno.2012.08.002. View

10.

Mohsen M, Bachmann M . Virus-like particle vaccinology, from bench to bedside. Cell Mol Immunol. 2022; 19(9):993-1011. PMC: 9371956. DOI: 10.1038/s41423-022-00897-8. View

11.

Mohsen M, Augusto G, Bachmann M . The 3Ds in virus-like particle based-vaccines: "Design, Delivery and Dynamics". Immunol Rev. 2020; 296(1):155-168. PMC: 7496916. DOI: 10.1111/imr.12863. View

12.

Lee K, Twyman R, Fiering S, Steinmetz N . Virus-based nanoparticles as platform technologies for modern vaccines. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016; 8(4):554-78. PMC: 5638654. DOI: 10.1002/wnan.1383. View

13.

Frietze K, Peabody D, Chackerian B . Engineering virus-like particles as vaccine platforms. Curr Opin Virol. 2016; 18:44-9. PMC: 4983494. DOI: 10.1016/j.coviro.2016.03.001. View

14.

Nguyen B, Tolia N . Protein-based antigen presentation platforms for nanoparticle vaccines. NPJ Vaccines. 2021; 6(1):70. PMC: 8119681. DOI: 10.1038/s41541-021-00330-7. View

15.

Lung P, Yang J, Li Q . Nanoparticle formulated vaccines: opportunities and challenges. Nanoscale. 2020; 12(10):5746-5763. DOI: 10.1039/c9nr08958f. View

16.

Mohsen M, Zha L, Cabral-Miranda G, Bachmann M . Major findings and recent advances in virus-like particle (VLP)-based vaccines. Semin Immunol. 2017; 34:123-132. DOI: 10.1016/j.smim.2017.08.014. View

17.

McFall-Boegeman H, Huang X . Mechanisms of cellular and humoral immunity through the lens of VLP-based vaccines. Expert Rev Vaccines. 2022; 21(4):453-469. PMC: 8960355. DOI: 10.1080/14760584.2022.2029415. View

18.

Bachmann M, Jennings G . Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010; 10(11):787-96. DOI: 10.1038/nri2868. View

19.

Shah R, OHagan D, Amiji M, Brito L . The impact of size on particulate vaccine adjuvants. Nanomedicine (Lond). 2014; 9(17):2671-81. DOI: 10.2217/nnm.14.193. View

20.

Zabel F, Kundig T, Bachmann M . Virus-induced humoral immunity: on how B cell responses are initiated. Curr Opin Virol. 2013; 3(3):357-62. DOI: 10.1016/j.coviro.2013.05.004. View